Subjects -> MEDICAL SCIENCES (Total: 8677 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (338 journals)
    - DENTISTRY (294 journals)
    - ENDOCRINOLOGY (151 journals)
    - FORENSIC SCIENCES (42 journals)
    - HEMATOLOGY (157 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (177 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2410 journals)
    - NURSES AND NURSING (367 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (386 journals)
    - OTORHINOLARYNGOLOGY (83 journals)
    - PATHOLOGY (100 journals)
    - PEDIATRICS (275 journals)
    - PSYCHIATRY AND NEUROLOGY (833 journals)
    - RESPIRATORY DISEASES (104 journals)
    - RHEUMATOLOGY (79 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (406 journals)

CARDIOVASCULAR DISEASES (338 journals)                  1 2 | Last

Showing 1 - 200 of 338 Journals sorted alphabetically
Acta Angiologica     Open Access   (Followers: 5)
Acta Cardiologica     Hybrid Journal   (Followers: 2)
Acute Cardiac Care     Hybrid Journal   (Followers: 8)
Adipositas - Ursachen, Folgeerkrankungen, Therapie     Hybrid Journal  
AJP Heart and Circulatory Physiology     Hybrid Journal   (Followers: 12)
Aktuelle Kardiologie     Hybrid Journal   (Followers: 1)
American Heart Journal     Hybrid Journal   (Followers: 60)
American Journal of Cardiology     Hybrid Journal   (Followers: 68)
American Journal of Cardiovascular Drugs     Hybrid Journal   (Followers: 18)
American Journal of Hypertension     Hybrid Journal   (Followers: 29)
Anales de Cirugia Vascular     Full-text available via subscription   (Followers: 1)
Anatolian Journal of Cardiology     Open Access   (Followers: 6)
Angiología     Full-text available via subscription  
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Angiology     Hybrid Journal   (Followers: 3)
Annales de Cardiologie et d'Angéiologie     Full-text available via subscription   (Followers: 1)
Annals of Circulation     Open Access   (Followers: 2)
Annals of Noninvasive Electrocardiology     Hybrid Journal   (Followers: 1)
Annals of Pediatric Cardiology     Open Access   (Followers: 12)
AORTA     Open Access  
Archives of Cardiovascular Diseases     Full-text available via subscription   (Followers: 6)
Archives of Cardiovascular Diseases Supplements     Full-text available via subscription   (Followers: 4)
Archives of Cardiovascular Imaging     Open Access   (Followers: 2)
Archivos de cardiología de México     Open Access   (Followers: 1)
Argentine Journal of Cardiology (English edition)     Open Access   (Followers: 2)
Arquivos Brasileiros de Cardiologia     Open Access   (Followers: 2)
Arrhythmia & Electrophysiology Review     Open Access   (Followers: 1)
Arteriosclerosis, Thrombosis and Vascular Biology     Full-text available via subscription   (Followers: 33)
Artery Research     Hybrid Journal   (Followers: 5)
ARYA Atherosclerosis     Open Access  
ASAIO Journal     Hybrid Journal   (Followers: 4)
ASEAN Heart Journal     Open Access   (Followers: 3)
Asian Cardiovascular and Thoracic Annals     Hybrid Journal   (Followers: 2)
Aswan Heart Centre Science & Practice Services     Open Access   (Followers: 1)
Atherosclerosis : X     Open Access  
Bangladesh Heart Journal     Open Access   (Followers: 3)
Basic Research in Cardiology     Hybrid Journal   (Followers: 9)
BMC Cardiovascular Disorders     Open Access   (Followers: 22)
Brain Circulation     Open Access   (Followers: 1)
British Journal of Cardiology     Full-text available via subscription   (Followers: 18)
Canadian Journal of Cardiology     Hybrid Journal   (Followers: 18)
Cardiac Cath Lab Director     Full-text available via subscription  
Cardiac Electrophysiology Review     Hybrid Journal   (Followers: 2)
Cardiac Failure Review     Open Access   (Followers: 2)
Cardiocore     Full-text available via subscription   (Followers: 1)
Cardiogenetics     Open Access   (Followers: 3)
Cardiology     Full-text available via subscription   (Followers: 20)
Cardiology and Angiology: An International Journal     Open Access   (Followers: 1)
Cardiology and Therapy     Open Access   (Followers: 11)
Cardiology Clinics     Full-text available via subscription   (Followers: 14)
Cardiology in Review     Hybrid Journal   (Followers: 9)
Cardiology in the Young     Hybrid Journal   (Followers: 35)
Cardiology Journal     Open Access   (Followers: 6)
Cardiology Plus     Open Access   (Followers: 1)
Cardiology Research     Open Access   (Followers: 15)
Cardiology Research and Practice     Open Access   (Followers: 11)
Cardiopulmonary Physical Therapy Journal     Hybrid Journal   (Followers: 9)
Cardiorenal Medicine     Full-text available via subscription   (Followers: 1)
Cardiothoracic Surgeon     Open Access   (Followers: 1)
CardioVasc     Full-text available via subscription   (Followers: 1)
Cardiovascular & Haematological Disorders - Drug Targets     Hybrid Journal   (Followers: 1)
Cardiovascular & Hematological Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 2)
CardioVascular and Interventional Radiology     Hybrid Journal   (Followers: 15)
Cardiovascular and Thoracic Open     Open Access  
Cardiovascular Diabetology     Open Access   (Followers: 10)
Cardiovascular Drugs and Therapy     Hybrid Journal   (Followers: 14)
Cardiovascular Endocrinology & Metabolism     Hybrid Journal   (Followers: 1)
Cardiovascular Engineering     Hybrid Journal   (Followers: 1)
Cardiovascular Engineering and Technology     Hybrid Journal   (Followers: 1)
Cardiovascular Intervention and Therapeutics     Hybrid Journal   (Followers: 5)
Cardiovascular Journal     Open Access   (Followers: 6)
Cardiovascular Journal of Africa     Full-text available via subscription   (Followers: 5)
Cardiovascular Journal of South Africa     Full-text available via subscription   (Followers: 2)
Cardiovascular Medicine in General Practice     Full-text available via subscription   (Followers: 7)
Cardiovascular Pathology     Hybrid Journal   (Followers: 4)
Cardiovascular Regenerative Medicine     Open Access  
Cardiovascular Research     Hybrid Journal   (Followers: 16)
Cardiovascular Revascularization Medicine     Hybrid Journal   (Followers: 1)
Cardiovascular System     Open Access  
Cardiovascular Therapeutics     Open Access   (Followers: 1)
Cardiovascular Toxicology     Hybrid Journal   (Followers: 6)
Cardiovascular Ultrasound     Open Access   (Followers: 5)
Case Reports in Cardiology     Open Access   (Followers: 7)
Catheterization and Cardiovascular Interventions     Hybrid Journal   (Followers: 3)
Cerebrovascular Diseases     Full-text available via subscription   (Followers: 3)
Cerebrovascular Diseases Extra     Open Access  
Chest     Full-text available via subscription   (Followers: 104)
Choroby Serca i Naczyń     Open Access   (Followers: 1)
Circulation     Hybrid Journal   (Followers: 269)
Circulation : Cardiovascular Imaging     Hybrid Journal   (Followers: 15)
Circulation : Cardiovascular Interventions     Hybrid Journal   (Followers: 19)
Circulation : Cardiovascular Quality and Outcomes     Hybrid Journal   (Followers: 12)
Circulation : Genomic and Precision Medicine     Hybrid Journal   (Followers: 17)
Circulation : Heart Failure     Hybrid Journal   (Followers: 28)
Circulation Research     Hybrid Journal   (Followers: 36)
Cirugía Cardiovascular     Open Access  
Clínica e Investigación en Arteriosclerosis     Full-text available via subscription  
Clínica e Investigación en arteriosclerosis (English Edition)     Hybrid Journal  
Clinical and Experimental Hypertension     Hybrid Journal   (Followers: 3)
Clinical Cardiology     Hybrid Journal   (Followers: 10)
Clinical Hypertension     Open Access   (Followers: 5)
Clinical Medicine Insights : Cardiology     Open Access   (Followers: 6)
Clinical Research in Cardiology     Hybrid Journal   (Followers: 5)
Clinical Research in Cardiology Supplements     Hybrid Journal  
Clinical Trials and Regulatory Science in Cardiology     Open Access   (Followers: 4)
Congenital Heart Disease     Hybrid Journal   (Followers: 6)
Congestive Heart Failure     Hybrid Journal   (Followers: 4)
Cor et Vasa     Full-text available via subscription   (Followers: 1)
Coronary Artery Disease     Hybrid Journal   (Followers: 3)
CorSalud     Open Access  
Critical Pathways in Cardiology     Hybrid Journal   (Followers: 5)
Current Cardiology Reports     Hybrid Journal   (Followers: 6)
Current Cardiology Reviews     Hybrid Journal   (Followers: 3)
Current Cardiovascular Imaging Reports     Hybrid Journal   (Followers: 1)
Current Cardiovascular Risk Reports     Hybrid Journal  
Current Heart Failure Reports     Hybrid Journal   (Followers: 5)
Current Hypertension Reports     Hybrid Journal   (Followers: 6)
Current Hypertension Reviews     Hybrid Journal   (Followers: 6)
Current Opinion in Cardiology     Hybrid Journal   (Followers: 13)
Current Problems in Cardiology     Hybrid Journal   (Followers: 3)
Current Research : Cardiology     Full-text available via subscription   (Followers: 1)
Current Treatment Options in Cardiovascular Medicine     Hybrid Journal   (Followers: 1)
Current Vascular Pharmacology     Hybrid Journal   (Followers: 5)
CVIR Endovascular     Open Access   (Followers: 1)
Der Kardiologe     Hybrid Journal   (Followers: 1)
Echo Research and Practice     Open Access   (Followers: 2)
Echocardiography     Hybrid Journal   (Followers: 4)
Egyptian Heart Journal     Open Access   (Followers: 2)
Egyptian Journal of Cardiothoracic Anesthesia     Open Access  
ESC Heart Failure     Open Access   (Followers: 4)
European Cardiology Review     Open Access   (Followers: 1)
European Heart Journal     Hybrid Journal   (Followers: 68)
European Heart Journal - Cardiovascular Imaging     Hybrid Journal   (Followers: 10)
European Heart Journal - Cardiovascular Pharmacotherapy     Full-text available via subscription   (Followers: 2)
European Heart Journal - Quality of Care and Clinical Outcomes     Hybrid Journal  
European Heart Journal : Acute Cardiovascular Care     Hybrid Journal   (Followers: 1)
European Heart Journal : Case Reports     Open Access   (Followers: 1)
European Heart Journal Supplements     Hybrid Journal   (Followers: 7)
European Journal of Cardio-Thoracic Surgery     Hybrid Journal   (Followers: 9)
European Journal of Cardio-Thoracic Surgery Supplements     Full-text available via subscription   (Followers: 2)
European Journal of Cardiovascular Nursing     Hybrid Journal   (Followers: 5)
European Journal of Heart Failure     Hybrid Journal   (Followers: 13)
European Journal of Preventive Cardiology.     Hybrid Journal   (Followers: 6)
European Stroke Organisation     Hybrid Journal   (Followers: 3)
Experimental & Translational Stroke Medicine     Open Access   (Followers: 9)
Expert Review of Cardiovascular Therapy     Full-text available via subscription   (Followers: 3)
Folia Cardiologica     Open Access  
Forum Zaburzeń Metabolicznych     Hybrid Journal  
Frontiers in Cardiovascular Medicine     Open Access   (Followers: 1)
Future Cardiology     Hybrid Journal   (Followers: 5)
General Thoracic and Cardiovascular Surgery     Hybrid Journal   (Followers: 3)
Global Cardiology Science and Practice     Open Access   (Followers: 5)
Global Heart     Hybrid Journal   (Followers: 3)
Heart     Hybrid Journal   (Followers: 49)
Heart and Mind     Open Access  
Heart and Vessels     Hybrid Journal  
Heart Failure Clinics     Full-text available via subscription   (Followers: 2)
Heart Failure Reviews     Hybrid Journal   (Followers: 3)
Heart India     Open Access   (Followers: 2)
Heart International     Full-text available via subscription  
Heart Rhythm     Hybrid Journal   (Followers: 11)
Heart Views     Open Access   (Followers: 2)
HeartRhythm Case Reports     Open Access  
Hellenic Journal of Cardiology     Open Access   (Followers: 1)
Herz     Hybrid Journal   (Followers: 2)
High Blood Pressure & Cardiovascular Prevention     Full-text available via subscription   (Followers: 2)
Hypertension     Full-text available via subscription   (Followers: 24)
Hypertension     Open Access   (Followers: 2)
Hypertension in Pregnancy     Hybrid Journal   (Followers: 9)
Hypertension Research     Hybrid Journal   (Followers: 4)
Ibrahim Cardiac Medical Journal     Open Access  
IJC Heart & Vessels     Open Access   (Followers: 1)
IJC Heart & Vasculature     Open Access   (Followers: 1)
IJC Metabolic & Endocrine     Open Access   (Followers: 1)
Indian Heart Journal     Open Access   (Followers: 5)
Indian Journal of Cardiovascular Disease in Women WINCARS     Open Access  
Indian Journal of Thoracic and Cardiovascular Surgery     Hybrid Journal  
Indian Pacing and Electrophysiology Journal     Open Access   (Followers: 1)
Innovations : Technology and Techniques in Cardiothoracic and Vascular Surgery     Hybrid Journal   (Followers: 1)
Insuficiencia Cardíaca     Open Access  
Interactive CardioVascular and Thoracic Surgery     Hybrid Journal   (Followers: 6)
International Cardiovascular Forum Journal     Open Access  
International Journal of Angiology     Hybrid Journal   (Followers: 2)
International Journal of Cardiology     Hybrid Journal   (Followers: 17)
International Journal of Cardiology Hypertension     Open Access   (Followers: 1)
International Journal of Cardiovascular and Cerebrovascular Disease     Open Access   (Followers: 3)
International Journal of Cardiovascular Imaging     Hybrid Journal   (Followers: 2)
International Journal of Cardiovascular Research     Hybrid Journal   (Followers: 6)
International Journal of Heart Rhythm     Open Access  
International Journal of Hypertension     Open Access   (Followers: 8)
International Journal of Hyperthermia     Open Access  
International Journal of Stroke     Hybrid Journal   (Followers: 33)
International Journal of the Cardiovascular Academy     Open Access  
Interventional Cardiology Clinics     Full-text available via subscription   (Followers: 2)
Interventional Cardiology Review     Open Access  
JACC : Basic to Translational Science     Open Access   (Followers: 6)
JACC : Cardiovascular Imaging     Hybrid Journal   (Followers: 19)
JACC : Cardiovascular Interventions     Hybrid Journal   (Followers: 21)
JACC : Heart Failure     Full-text available via subscription   (Followers: 16)
JAMA Cardiology     Hybrid Journal   (Followers: 31)

        1 2 | Last

Similar Journals
Journal Cover
Clinical Trials and Regulatory Science in Cardiology
Journal Prestige (SJR): 0.365
Citation Impact (citeScore): 1
Number of Followers: 4  

  This is an Open Access Journal Open Access journal
ISSN (Print) 2405-5875
Published by Elsevier Homepage  [3203 journals]
  • Novel Vascular Indices Evaluated Non-Invasively in End-stage Renal Disease
           Patients on Hemodialysis

    • Authors: Daisuke Sueta; Eiichiro Yamamoto; Yoshihiro Hirata; Takanori Tokitsu; Kenji Sakamoto; Kenichi Tsujita; Koichi Kaikita; Seiji Hokimoto; Toshihiko Sakanashi; Hisao Ogawa
      Pages: 1 - 3
      Abstract: Publication date: Available online 11 September 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Daisuke Sueta, Eiichiro Yamamoto, Yoshihiro Hirata, Takanori Tokitsu, Kenji Sakamoto, Kenichi Tsujita, Koichi Kaikita, Seiji Hokimoto, Toshihiko Sakanashi, Hisao Ogawa

      PubDate: 2015-09-15T09:32:23Z
      DOI: 10.1016/j.ctrsc.2015.09.001
      Issue No: Vol. 9 (2015)
  • A Case of Spontaneous and Simultaneous Dissections of Both Common Iliac
           Arteries in a Young Patient

    • Authors: Daisuke Sueta; Seiji Hokimoto; Ryo Hirayama; Ryusuke Suzuki; Hisao Ogawa
      Pages: 4 - 5
      Abstract: Publication date: Available online 11 September 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Daisuke Sueta, Seiji Hokimoto, Ryo Hirayama, Ryusuke Suzuki, Hisao Ogawa

      PubDate: 2015-09-15T09:32:23Z
      DOI: 10.1016/j.ctrsc.2015.09.002
      Issue No: Vol. 9 (2015)
  • Increased risk for vascular complications due to GP IIb/ IIIa- antagonists
           in patients with cardiogenic shock supported by intraaortic balloon pump

    • Authors: Jens Röther; Monique Tröbs; Annika Schuhbäck; Josef Ludwig; Stephan Achenbach; Christian Schlundt
      Pages: 1 - 3
      Abstract: Publication date: Available online 30 August 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Jens Röther, Monique Tröbs, Annika Schuhbäck, Josef Ludwig, Stephan Achenbach, Christian Schlundt
      Background IABP is routinely used to support coronary blood flow and systemic circulation in patients with cardiogenic shock. Our aim was to explore the incidence of vascular complications associated with the use of IABP in this scenario and their influence on mortality. Methods Therefor we analysed 204 consecutive patients between 2002 and 2013 treated with IAPB in cardiogenic shock for vascular complications and mortality within 30 days after implantation of IAPB. Primary endpoints were severe bleeding (TIMI- definition: intracranial bleeding, loss of haemoglobin (Hb) > 5g/dl or hematocrit (PCV) >15%), vascular complications with therapeutic consequence (venous thrombosis, arterial embolism) and stroke. Results 80 (39%) patients died within 30 days after implantation of IABP. In 42 (21%) patients vascular complications occurred: severe bleeding was present in 26 patients (62% of all complications), 13 (31%) patients suffered from venous thrombosis or arterial embolism and 3 (7%) patients from stroke. 25% of the patients who died had a vascular complication. The rate in patients who overcame cardiogenic shock was 17,7% (p=0.22). Multivariate analyses showed treatment with Glycoprotein (GP) IIb/IIIa- inhibitors to be an independent risk factor for the occurrence of vascular complications (p=0.04). Conclusion Vascular events with the use of IABP are common but in our study not significantly associated with a higher mortality. Treatment with GP IIb/ IIIa- antagonists is associated with a higher risk of vascular events.

      PubDate: 2015-09-01T08:32:01Z
      DOI: 10.1016/j.ctrsc.2015.08.008
      Issue No: Vol. 8 (2015)
  • Safety and performance of the next generation EnligHTN™ renal
           denervation system in patients with drug-resistant, uncontrolled
           hypertension: The EnligHTN III first-in-human multicentre study

    • Authors: Stephen G. Worthley; Gerard T. Wilkins; Mark W. Webster; Joseph K. Montarello; Paul R. Antonis; Robert J. Whitbourn; Roderic J. Warren
      Pages: 4 - 10
      Abstract: Publication date: Available online 31 August 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Stephen G. Worthley, Gerard T. Wilkins, Mark W. Webster, Joseph K. Montarello, Paul R. Antonis, Robert J. Whitbourn, Roderic J. Warren
      Background/Objectives Catheter-based renal denervation for the treatment of drug-resistant hypertension has been intensively investigated in recent years. To date, only limited data have been published using multi-electrode radiofrequency ablation systems that can deliver lesions with a pre-determined pattern. This study was designed to evaluate the safety and efficacy of the next generation EnligHTN™ renal denervation system. Six-month primary endpoint data are presented here. Methods We conducted this first-in-human, prospective, multi-centre, non-randomized study in 39 patients (62% male, mean age 63years, and mean baseline office blood pressure 174/93mmHg) with drug-resistant hypertension. The primary safety and efficacy objectives were to characterize, from baseline to 6months post procedure, the rate of serious procedural and device related adverse events, as adjudicated by an independent Clinical Events Committee, and the reduction of office systolic blood pressure. Results Renal artery denervation, using the next generation EnligHTN multi-electrode system significantly reduced office blood pressure from baseline to 1, 3, and 6months by −19/7, −26/9 and −25/7mmHg, respectively (P≤0.0005). No serious device or procedure related adverse events affecting the renal arteries or renal function occurred through. Conclusions Renal sympathetic denervation using the next generation EnligHTN renal denervation system resulted in safe, rapid, and significant mean office blood pressure reduction that was sustained through 6months. Future studies will need to address the utility of this system against an appropriate placebo based comparator.

      PubDate: 2015-09-01T08:32:01Z
      DOI: 10.1016/j.ctrsc.2015.08.007
      Issue No: Vol. 8 (2015)
  • Three-Dimensional Binding Sites Volume Assessment during Cardiac Pacing
           Lead Extraction

    • Authors: Bich Lien Nguyen; Alessandro Persi; Eli S. Gang; Fabrizio Fattorini; Alessandra Oliva; Antonio Vitarelli; Nicola Alessandri; Robert J. Siegel; Antonio Ciccaglioni; Carlo Gaudio
      Pages: 1 - 6
      Abstract: Publication date: Available online 28 August 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Bich Lien Nguyen, Alessandro Persi, Eli S. Gang, Fabrizio Fattorini, Alessandra Oliva, Antonio Vitarelli, Nicola Alessandri, Robert J. Siegel, Antonio Ciccaglioni, Carlo Gaudio
      Background/Objectives Binding sites are the principal cause of failed lead removal and complications, and are not directly visualized by fluoroscopy. We aimed to assess binding sites between permanent cardiac pacing leads and cardiovascular structures using CartoSound™ three-dimensional (3D) imaging technology (Biosense Webster Inc, Diamond Bar, CA) during transvenous lead extraction, and compared outcomes to standard approach. Methods We recruited 291 patients undergoing percutaneous lead extraction, and 3D CartoSound anatomical mapping of the superior vena cava, right atrium (RA), coronary sinus, right ventricle (RV), pacing leads, and binding sites before, during, and after lead removal was randomly performed in 46 of them (38 men; mean age 73.7±10.5years; 1.96 leads/patient; mean time-from-implant of 62.7±51.8months) using a 10-Fr 3D SoundStar™ catheter and integrated into the Carto® mapping system. Results CartoSound was able to detect more intracardiac binding sites compared to fluoroscopy (RA 17.4% vs. 4.3%, p=0.04; RV 43.5% vs. 21.7%, p=0.04), but was unable to assess the subclavian/innominate veins. Binding sites volume correlated positively with time-from-implant (r=0.38, p<0.05), and powered-sheaths use (r=0.39, p<0.05), and negatively with procedural success (r=−0.37, p<0.05). When compared to standard approach, CartoSound use was characterized by a significantly lower mean procedure time (p=0.0001), and major complications (p=0.03), and greater procedure success rates (p=0.03). Conclusions Real-time 3D binding sites assessment is feasible and improves transvenous lead extraction outcomes. Its role as a complementary information requires extensive validation, and might be beneficial for a tailored strategy.

      PubDate: 2015-09-01T08:32:01Z
      DOI: 10.1016/j.ctrsc.2015.08.006
      Issue No: Vol. 7 (2015)
  • Optimize the Duration of DAPT Following DES Implantation: An updated
           System Review and Meta-Analysis of 10 Randomized Trials

    • Authors: Xin-Lin Zhang; Qing-Qing Zhu; Li Zhu; Su-Qin Shi; Jian-Zhou Chen; Jun Xie; Wei Huang; Biao Xu
      Pages: 1 - 11
      Abstract: Publication date: Available online 12 August 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Xin-Lin Zhang, Qing-Qing Zhu, Li Zhu, Su-Qin Shi, Jian-Zhou Chen, Jun Xie, Wei Huang, Biao Xu
      Background The appropriate duration of dual antiplatelet therapy (DAPT) with aspirin and a thienopyridine following drug-eluting stenting in percutaneous coronary intervention (PCI) remains uncertain. Methods and Results A systemic search was conducted in PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL), for randomized trials evaluating the relative efficacy and safety performance of an extended with a control duration DAPT after drug-eluting stents (DES) implantation. Ten trials including 32135 patients were included. Compared with DAPT of 3 to 6months, an extended DAPT duration of 12months or longer significantly increased risk of major bleeding by 90% (RR: 1.90, 95% CI: 1.23 to 2.94, p =0.004), but did not reduced incidences of any documented ischemic events. Compared with 12-month duration, a more extended DAPT (18 to 30months) significantly increased risk of all-cause death (RR: 1.30, 95% CI: 1.02 to 1.65, p =0.035) and major bleeding (RR: 1.61, 95% CI: 1.25 to 2.07, p <0.001), decreased risk of myocardial infarction (RR: 0.53, 95% CI: 0.43 to 0.66, p <0.001) and stent thrombosis (RR: 0.33, 95% CI: 0.21 to 0.51, p <0.001), no difference was detected regarding cardiac death and stroke. Conclusions A short DAPT (3 to 6months) decreases major bleeding while maintains antithrombotic efficacy compared with an extended DAPT (≥12months). A more extended DAPT (18 to 30months) decreases ischemic events, whereas increases risks of all-cause death and major bleeding than standard 12-month therapy. A 3-to-6-month DAPT might be preferable for a broad group of patients undergoing DES implantation.

      PubDate: 2015-08-17T06:22:14Z
      DOI: 10.1016/j.ctrsc.2015.08.003
      Issue No: Vol. 6 (2015)
  • Galectin-3 and Incident Heart Failure among Patients with Pre-existing
           Coronary Artery Disease: the ADVANCE Study

    • Authors: Carlos Iribarren; Malini Chandra; Jamal S. Rana; Mark A. Hlatky; Stephen P. Fortmann; Thomas Quertermous; Alan S. Go
      Pages: 1 - 7
      Abstract: Publication date: Available online 12 August 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Carlos Iribarren, Malini Chandra, Jamal S. Rana, Mark A. Hlatky, Stephen P. Fortmann, Thomas Quertermous, Alan S. Go
      Background Galectin-3 (Gal-3) is a novel fibrosis biomarker. We ascertained: 1) the correlates of Gal-3, and 2) its association with incident heart failure among 1,312 participants in The ADVANCE Study (871 subjects with acute myocardial infarction [AMI] and 441 subjects with stable angina). Methods Cohort design, with Gal-3 measured in stored baseline serum samples (2002–04). After a median (SD) follow-up of 8.1 (3.2) years, 74 incident heart failure events were documented. Results The significant independent correlates of Gal-3 were age, gender, diabetes, C-reactive protein and estimated glomerular filtration rate. In Cox regression with adjustment for these variables plus race, CAD presentation, smoking status, body mass index, hypertension and cholesterol lowering drugs, there was a 1.51-fold (95% CI, 1.24 to 1.85; p<0.0001) increased hazard of heart failure for each SD linear increment in Gal-3. In the fully-adjusted model, quartile four of Gal-3 (relative to quartile one) was associated with 2.1-fold increased hazard of heart failure (95% CI, 1.05 to 4.2). The C-statistic increased to 0.78 from 0.75 (p=0.12) and the net reclassification index was 0.13 (SE=0.06; p=0.03) after adding Gal-3 quartiles to the model containing all risk factors. Conclusions Gal-3 is a useful marker of heart failure risk among patients with pre-existing coronary disease and may play an etiological role in the development of heart failure.

      PubDate: 2015-08-17T06:22:14Z
      DOI: 10.1016/j.ctrsc.2015.08.002
      Issue No: Vol. 5 (2015)
  • Endothelin Receptor Antagonism in Single Ventricle Physiology with Fontan
           Palliation: A Systematic Review and Meta-analysis

    • Authors: Gwendolyn Derk; Ruopeng An; Jamil Aboulhosn
      Pages: 1 - 5
      Abstract: Publication date: Available online 21 August 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Gwendolyn Derk, Ruopeng An, Jamil Aboulhosn
      Background The prevalence of single ventricle patients palliated with Fontan operation continues to grow worldwide. This study systematically reviewed existing evidence and performed a meta-analysis to determine the safety and efficacy of endothelin receptor antagonism in single ventricle physiology with Fontan palliation. Methods Keyword and reference search was conducted in PubMed Cochrane Library, Web of Science, Google Scholar, and databases. Inclusion criteria were – study design: randomized controlled trials, cohort studies, prospective studies, or retrospective studies subjects: single ventricle patients with Fontan palliation main outcome: exercise or functional capacity language: English and article type: peer-reviewed publications Results Five studies met the inclusion criteria, including three pre-post studies, one randomized crossover open label clinical trial, and one double-blind randomized controlled clinical trial. Study durations ranged from 3.5 to 6months, with a total sample size of 123. Bosentan was the single endothelin receptor blocker used in all studies. No significant increase in liver toxicity or other serious adverse event was reported in these studies. Meta-analysis found bosentan use to be associated with improvement in functional class (p=0.0007); whereas no significant change in six-minute walk distance, resting oxygen saturation, and maximal oxygen consumption was identified. Conclusions Bosentan was found to be a safe and well tolerated endothelin receptor antagonist in Fontan patients over 3–6 months of therapy. Bosentan use was associated with improved functional capacity. Future studies with larger sample size and longer duration are warranted to examine the long-term safety and efficacy of endothelin blockade in Fontan physiology.

      PubDate: 2015-08-27T08:10:46Z
      DOI: 10.1016/j.ctrsc.2015.08.001
      Issue No: Vol. 4 (2015)
  • Transparency in medical research: Time for a paradigm shift

    • Authors: Francesco Pelliccia; Andrew J.S. Coats; Luca Pani; Carlo Gaudio; Giuseppe Rosano
      Pages: 259 - 260
      Abstract: Publication date: Available online 14 May 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Francesco Pelliccia , Andrew J.S. Coats , Luca Pani , Carlo Gaudio , Giuseppe Rosano

      PubDate: 2015-05-14T12:58:14Z
      DOI: 10.1016/j.ijcard.2015.03.219
      Issue No: Vol. 186 (2015)
  • Adaptive licensing – A way forward in the approval process of new
           therapeutic agents in Europe

    • Authors: Giuseppe M.C. Rosano; Stefan D. Anker; Walter Marrocco; Andrew J.S. Coats
      Pages: 568 - 569
      Abstract: Publication date: Available online 4 February 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Giuseppe M.C. Rosano , Stefan Anker , Walter Marrocco , Andrew J.S. Coats

      PubDate: 2015-04-30T08:40:32Z
      DOI: 10.1016/j.ijcard.2015.02.112
      Issue No: Vol. 184 (2015)
  • From a Cardio-Vascular Reserve hypothesis to a proposed measurable index:
           a pilot empirical validation

    • Authors: Uri Gabbay; Ben-Zion Bobrovsky; Issahar Ben-Dov; Ronen Durst; Itay E. Gabbay; Michael J. Segel
      Pages: 1 - 5
      Abstract: Publication date: Available online 19 October 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Uri Gabbay, Ben-Zion Bobrovsky, Issahar Ben-Dov, Ronen Durst, Itay E. Gabbay, Michael J. Segel
      Background Cardiovascular Reserve Index (CVRI) was previously proposed as an estimate of the assumed (momentary) cardiovascular reserve as a function of Stroke Volume (SV), Systemic Vascular Resistance (SVR), Respiratory Rate (RR) and Body Surface Area (BSA). Conversion through conventional hemodynamic equations reveals an equivalent, simpler, vital signs based function. We evaluated the association between CVRI and diverse conditions along the hemodynamic spectrum. Methods CVRI was retrospectively computed for each subject of 3 existing patient databases. 1) Acute severe hospital admissions [N=333] classified by disease course to: “shock on arrival”, “developing shock” and “non-shock”. 2) Heart failure (HF) patients [N=71] classified by HF severity to: mild, moderate and severe HF. 3) Cardio-pulmonary exercise testing (CPX) [n=387] classified by exercise capacity (EC) to: normal, mildly decrease, moderately decrease and severely decreased EC. CVRI association with these hemodynamic conditions was evaluated through ANOVA. Results ‘normal EC’ has the highest CVRI of 0.97 (0.88,1.06), and in decreasing CVRI order ‘mildly decrease EC’, ‘moderately decrease EC’, ‘mild HF’ which was similar to ‘severely decrease EC’, ‘moderate HF’ which was similar to acute severe admission of ‘non-shock’, ‘sever heart failure’ which was similar to ‘developing shock’ and the lowest CVRI was observed in ‘shock on arrival’ with mean CVRI of 0.20 (0.19,0.22), ANOVA p<0.001. Conclusions Mean CVRI exhibited consistent inverse association with the severity of the hemodynamic condition. However, CVRI clinical utility of an individual patient requires further studies.

      PubDate: 2015-10-26T07:25:44Z
      DOI: 10.1016/j.ctrsc.2015.10.005
      Issue No: Vol. 12 (2015)
  • The incidence of symptomatic venous thromboembolism following hip
           fractures with or without surgery in Taiwan

    • Authors: Cheng-Han Lee; Tzu-Chieh Lin; Ching-Lan Cheng; Li-Jen Lin; Chyun-Yu Yang; Yea-Huei Kao Yang
      Pages: 6 - 11
      Abstract: Publication date: Available online 21 October 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Cheng-Han Lee, Tzu-Chieh Lin, Ching-Lan Cheng, Li-Jen Lin, Chyun-Yu Yang, Yea-Huei Kao Yang
      Background Information on the incidence of venous thromboembolism (VTE) following hip fractures in Asia is rare. This study will investigate the epidemiology of symptomatic VTE in Taiwanese patients experiencing hip fractures. Methods and results We used Taiwan's National Health Insurance Research Database to retrospectively identify patients (≧45years) who experienced hip fractures from 1998 to 2007 and were followed up for 3months after the discharge. Logistic regression analysis determined the independent risk factors of symptomatic VTE after the fractures. We identified 134,034 patients (mean age: 76.2±9.7years; female: 57.8%) who experienced hip fractures, 83.2% of whom underwent hip surgery. The overall pharmacological thromboprophylaxis rate was 2.7%. The mean length of stay was 11.3±7.9days. The 3-month cumulative incidence of symptomatic VTE was 77 events per 10,000 persons. Multivariate analysis showed that previous DVT, previous PE, varicose veins, cancer, heart failure, renal insufficiency, and older age were independent risk factors of developing VTE. Conclusions The incidence of symptomatic VTE after hip fractures is low in Taiwan. Patients rarely received pharmacological thromboprophylaxis following hip fractures. Universal thromboprophylaxis for patients experiencing hip fractures was not necessary in Taiwan, but it should be considered in high-risk populations.

      PubDate: 2015-10-26T07:25:44Z
      DOI: 10.1016/j.ctrsc.2015.10.001
      Issue No: Vol. 12 (2015)
  • Seasonal variations in nocturnal changes in blood pressure between Ireland
           and Singapore

    • Authors: Lin Ho Wong; Peter Ting; David Kerins
      Pages: 12 - 17
      Abstract: Publication date: December 2015
      Source:Clinical Trials and Regulatory Science in Cardiology, Volume 12
      Author(s): Lin Ho Wong, Peter Ting, David Kerins
      Background Normal blood pressure (BP) follows a circadian rhythm, with dipping of BP at night. However, knowledge is limited in how the nocturnal dipping in hypertensive patients changes with the seasons. The study aims to examine the pattern of seasonal changes of nocturnal dip in an Irish population and furthermore, to compare it to the pattern observed near the equator where such seasonal variations are minimal, by also studying a Singaporean population. Methods Ambulatory Blood Pressure Monitor recordings were obtained from 220 patients, half were from Mercy University Hospital, Cork, Ireland and half from the National Heart Centre, Singapore during the summer period from May to June and the winter period from October to December. Results Irish seasonal changes resulted in an increase in nocturnal dipping in the hypertensive patients, especially for diastolic pressure (95% CI, 0.72 to 6.03, 3.37mmHg; p<0.05) and a change in the duration of dipping at night (95% CI, 0.045 to 1.01, 0.53h; p<0.05). In Singapore, slight differences in dipping in systolic pressure were apparent despite the presence of only minor alterations in temperature (95% CI, 0.38 to 4.83, 2.61mmHg; P<0.05) or duration of daylight. Conclusion Seasonal changes not only affected the daily blood pressure but also the night time dipping status in hypertensive patients by mean value of 1.99mmHg and 3.38mmHg for systolic and diastolic pressure dip respectively. This has implications on how hypertensive patients should be treated during different seasons and when they are traveling to countries of different climatic environment.

      PubDate: 2015-11-04T16:02:58Z
      DOI: 10.1016/j.ctrsc.2015.10.006
      Issue No: Vol. 12 (2015)
  • The impact of beat-to-beat variability in optimising the acute hemodynamic
           response in cardiac resynchronisation therapy

    • Authors: Steven Niederer; Cameron Walker; Andrew Crozier; Eoin R. Hyde; Bojan Blazevic; Jonathan M. Behar; Simon Claridge; Manav Sohal; Anoop Shetty; Tom Jackson; Christopher Rinaldi
      Pages: 18 - 22
      Abstract: Publication date: Available online 21 October 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Steven Niederer, Cameron Walker, Andrew Crozier, Eoin R. Hyde, Bojan Blazevic, Jonathan M. Behar, Simon Claridge, Manav Sohal, Anoop Shetty, Tom Jackson, Christopher Rinaldi
      Background Acute indicators of response to cardiac resynchronisation therapy (CRT) are critical for developing lead optimisation algorithms and evaluating novel multi-polar, multi-lead and endocardial pacing protocols. Accounting for beat-to-beat variability in measures of acute haemodynamic response (AHR) may help clinicians understand the link between acute measurements of cardiac function and long term clinical outcome. Methods and results A retrospective study of invasive pressure tracings from 38 patients receiving an acute pacing and electrophysiological study was performed. 602 pacing protocols for left ventricle (LV) (n=38), atria–ventricle (AV) (n=9), ventricle–ventricle (VV) (n=12) and endocardial (ENDO) (n=8) optimisation was performed. AHR was measured as the maximal rate of LV pressure development (dP/dtMx) for each beat. The range of the 95% confidence interval (CI) of mean AHR was ~7% across all optimisation protocols compared with the reported CRT response cut off value of 10%. A single clear optimal protocol was identifiable in 61%, 22%, 25% and 50% for LV, AV, VV and ENDO optimisation cases, respectively. A level of service (LOS) optimisation that aimed to maxims the expected AHR 5th percentile, minimising variability and maximising AHR, led to distinct optimal protocols from conventional mean AHR optimisation in 34%, 78%, 67% and 12.5% of LV, AV, VV and ENDO optimisation cases, respectively. Conclusion The beat-to-beat variation in AHR is significant in the context of CRT cut off values. A LOS optimisation offers a novel index to identify the optimal pacing site that accounts for both the mean and variation of the baseline measurement and pacing protocol.

      PubDate: 2015-10-26T07:25:44Z
      DOI: 10.1016/j.ctrsc.2015.10.004
      Issue No: Vol. 12 (2015)
  • Impact of renal sympathetic denervation on home blood pressure monitoring
           in well defined patients with resistant hypertension

    • Authors: K.F. Franzen; M. Reppel; M. Neuwirth; J. Köster; T. Graf; F. Bode; J. Weil; K. Mortensen
      Pages: 23 - 27
      Abstract: Publication date: Available online 9 October 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): K.F. Franzen, M. Reppel, M. Neuwirth, J. Köster, T. Graf, F. Bode, J. Weil, K. Mortensen

      PubDate: 2015-10-10T20:36:32Z
      DOI: 10.1016/j.ctrsc.2015.09.005
      Issue No: Vol. 12 (2015)
  • The predictors of dislodgement and outcomes of transcatheter closure of
           complex atrial septal defects in adolescents and adults

    • Authors: Wei-Chieh Lee; Chih-Yuan Fang; Chien-Fu Huang; Ying-Jui Lin; Chiung-Jen Wu; Hsiu-Yu Fang
      Pages: 1 - 5
      Abstract: Publication date: November 2015
      Source:Clinical Trials and Regulatory Science in Cardiology, Volume 11
      Author(s): Wei-Chieh Lee, Chih-Yuan Fang, Chien-Fu Huang, Ying-Jui Lin, Chiung-Jen Wu, Hsiu-Yu Fang
      Objective Technical difficulties still exist for the catheter closure of atrial septal defects (ASD) in some of the morphological features of defects, or hemodynamic features in the population. The morphological or hemodynamic features are (1) large ASD, (2) wide rim deficiency, (3) multiple defects, (4) severe pulmonary hypertension, (5) ventricular dysfunction, and (6) restrictive left ventricular compliance. Our study aimed to assess the efficacy of transcatheter closure of complex ASDs under transesophageal echocardiography (TEE) guidance in adolescents and adults, and figured out the predictors of atrial septum occluder (ASO) dislodgement. Methods From June 2003 to June 2014, 125 adults and 12 adolescents were diagnosed with secundum ASD and underwent a transcatheter closure of defects using an ASO. Among the above patients, 63 patients had morphological or hemodynamic features that made ASD closure difficult. Results No ASO dislodgement occurred in the non-complex ASD closure group, and an 88.9% success rate was observed in the complex ASD closure group. Higher Qp/Qs ratio, higher incidence of multiple ASDs, and larger ASD size in the complex ASD closure group were noted. 50.8% patients in complex ASD closure group had ASD≧30mm. Multivariate analysis demonstrated that an occurrence of eroded and IAS or aneurysm formation and arrhythmia during implantation were independent predictors for ASO dislodgement in complex ASD closure (p=0.005; p=0.037). Conclusion Eroded and floppy IAS or aneurysm formation post ASO implantation and peri-procedure arrhythmia could predict ASO dislodgement in complex ASD closure. Transcatheter closure of ASDs under TEE guidance is feasible in complex cases.

      PubDate: 2015-10-30T07:38:38Z
      DOI: 10.1016/j.ctrsc.2015.10.002
      Issue No: Vol. 11 (2015)
  • Hyponatremia in Chagas disease heart failure: prevalence, clinical
           characteristics, and prognostic importance

    • Authors: Reinaldo B. Bestetti; Augusto Cardinalli-Neto; Ana Paula Otaviano; Marcelo A. Nakazone; Natália D. Bertolino; Paulo R. Nogueira
      Pages: 6 - 9
      Abstract: Publication date: Available online 25 September 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Reinaldo B. Bestetti, Augusto Cardinalli-Neto, Ana Paula Otaviano, Marcelo A. Nakazone, Natália D. Bertolino, Paulo R. Nogueira

      PubDate: 2015-09-25T15:14:13Z
      DOI: 10.1016/j.ctrsc.2015.09.003
      Issue No: Vol. 11 (2015)
  • Experiences with the Absorb everolimus-eluting bioresorbable vascular
           scaffold in all comers: the St. Antonius hospital single centre registry

    • Authors: K. Teeuwen; S. Hubbers; Jan G.P. Tijssen; J.A.S. Van Der Heyden; B.J.W.M. Rensing; M.J. Suttorp
      Pages: 1 - 6
      Abstract: Publication date: Available online 30 September 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): K. Teeuwen, S. Hubbers, Jan G.P. Tijssen, J.A.S. Van Der Heyden, B.J.W.M. Rensing, M.J. Suttorp
      Background Data on procedural and clinical outcomes of the everolimus-eluting bioresorbable vascular scaffold (BVS, Abbott) in percutaneous coronary intervention in a real-world setting is limited. Early and mid-term clinical outcome of the BVS in a real-world population were investigated in this single centre study. Methods Patients treated with the BVS in the St. Antonius Hospital from April 2012 to February 2015 were included in a prospective single centre registry. Procedural success defined as <20% residual restenosis and 30-day and 6-month clinical outcome were investigated. Cumulative event rates were expressed using Kaplan-Meijer method. Results A total of 108 patients were included in the study, including patients with ST-segment elevation myocardial infarction (STEMI) 18.5%, non-STEMI 22.2% and unstable angina 9.3%. In total 125 lesions were treated with the BVS, of which 48.8% B2/C type lesions including 19.2% bare metal or drugs-eluting in-stent restenosis. Procedural angiographic success was achieved in 99.2% of all patients. Clinical follow-up rate was 100% at 30-day and 87% at 6-month. The rate of cardiac death, target vessel revascularization and definite stent thrombosis was 0%, 0.9% and 0.9% at 30-day and 0.9%, 5.6% and 1.9% at 6-month. The composite end point of target lesion failure (Cardiac death, target lesion myocardial infarction MI and target lesion revascularization) was 1.9% at 30-day and 5.6% at 6-month, respectively. Conclusions The use of the BVS in a real-world setting demonstrated excellent procedural success and acceptable mid-term clinical outcomes. The rate of definite scaffold thrombosis was not dissimilar to other BVS registries.

      PubDate: 2015-10-05T19:30:21Z
      DOI: 10.1016/j.ctrsc.2015.09.004
      Issue No: Vol. 10 (2015)
  • Platelet Reactivity Following High Loading Doses of Clopidogrel in
           Patients Undergoing Primary Percutaneous Coronary Angioplasty: A Pilot

    • Authors: Kuljit Singh; George A. Wells; Derek Y. So; Christopher A. Glover; Michael Froeschl; Jean-François Marquis; Edward R. O'Brien; Benjamin Hibbert; Aun Yeong Chong; Alexander Dick; James Weaver; Marino Labinaz; Michel R. Le May
      Pages: 7 - 12
      Abstract: Publication date: Available online 30 September 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Kuljit Singh, George A. Wells, Derek Y. So, Christopher A. Glover, Michael Froeschl, Jean-François Marquis, Edward R. O'Brien, Benjamin Hibbert, Aun Yeong Chong, Alexander Dick, James Weaver, Marino Labinaz, Michel R. Le May
      Background Rapid inhibition of platelet function is critical in patients referred for primary percutaneous coronary intervention (PCI) to prevent stent thrombosis. We sought to determine the antiplatelet effects of two clopidogrel high loading dose (LD) strategies on platelet reactivity in patients presenting with ST-elevation myocardial infarction (STEMI). Methods Patients referred for primary PCI were randomly assigned to one of two clopidogrel LDs initiated before catheterization: 600mg vs. 600/600mg (second dose 3h after first LD). Platelet function testing was performed at baseline, and at 1, 2, 4, 6, 24, and 48h after the initial LD using the VerifyNow device. The primary endpoint was the proportion of patients with high platelet reactivity (HPR) at 24h defined as a P2Y12 reaction unit (PRU) measurement >208. Results Fifty-four patients were assigned to clopidogrel as a single 600mg LD (n=27) or as a 600/600mg double LD (n=27). The proportion of patients with HPR at 24h was recorded in 44.0% assigned to the 600mg LD and 24.0% of patients assigned to 600/600mg LD, p=0.23. The mean PRU at 24h was 191±102 in the 600mg group and 152±94 in the 600/600mg group, p=0.16. There was no difference at all time points in HPR, and in mean PRUs between the LD regimens. Conclusions High platelet reactivity persisted at 24h in a significant proportion of patients referred for primary PCI regardless of two clopidogrel high LD strategies. These results may have implications regarding the risk of early stent thrombosis in STEMI patients treated with clopidogrel.

      PubDate: 2015-10-05T19:30:21Z
      DOI: 10.1016/j.ctrsc.2015.09.006
      Issue No: Vol. 10 (2015)
  • The prevalence and prognosis of contrast-induced acute kidney injury
           according to the definition in patients with acute myocardial infarction
           who underwent primary percutaneous coronary intervention

    • Authors: Osamu Kuboyama; Takeshi Tokunaga
      Abstract: Publication date: Available online 2 December 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Osamu Kuboyama, Takeshi Tokunaga
      Background Contrast-induced acute kidney injury (CI-AKI) is associated with adverse outcomes. However, the problem complicating CI-AKI relates to its definition. More than 30 definitions of AKI have been used in the literature. We examined the prevalence of CI-AKI according to three criteria. Prevalence of cardiovascular events according to each criterion was also investigated. Methods We studied 247 consecutive patients with acute myocardial infarction (66.7 ± 9.0 years, 189 males) who underwent primary percutaneous coronary intervention in our hospital. Three definitions of CI-AKI were applied: (i) traditional CI-AKI, (ii) CI-AKI derived from RIFLE criteria, (iii) CI-AKI derived from AKIN criteria. Cardiovascular events comprised in-hospital death, sudden death, cerebral infarction, heart failure, and acute coronary syndrome. Results Prevalence of CI-AKI was 27.1% (67/247) according to the traditional CI-AKI definition, 23.9% (59/247) according to the CI-AKI definition derived from RIFLE criteria, and 15.8% (39/247) according to the CI-AKI definition derived from AKIN criteria. Prevalence of cardiovascular events was 13.8% (34/247). Prevalence of cardiovascular events with and without CI-AKI was 19.4% (13/67) and 11.7% (21/180) according to the traditional CI-AKI definition (p = 0.13), 22.0% (13/59) and 11.2% (21/188) in the CI-AKI definition derived from RIFLE criteria (p = 0.035), and 35.9%(14/39) and 9.6% (20/208) according to the CI-AKI derived from AKIN criteria (p = 0.00001). Conclusion: Prevalence of CI-AKI varies widely depending on the criteria used. The CI-AKI definition derived from AKIN criteria was the most effective predictor of cardiovascular events.

      PubDate: 2015-12-05T00:53:18Z
  • Baroreflex activation therapy: A new avenue for heart failure treatment

    • Authors: Edoardo Gronda; Eric Lovett Emilio Vanoli
      Abstract: Publication date: Available online 2 December 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Edoardo Gronda, Eric G. Lovett, Emilio Vanoli

      PubDate: 2015-12-05T00:53:18Z
  • Comparative effects of high intensity interval training versus moderate
           intensity continuous training on quality of life in patients with heart
           failure: Study protocol for a randomized controlled trial

    • Authors: Anderson Zampier; Ulbrich Vitor Giatte Angarten Almir Schmitt Netto Sabrina
      Abstract: Publication date: Available online 23 November 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Anderson Zampier Ulbrich, Vitor Giatte Angarten, Almir Schmitt Netto, Sabrina Weiss Sties, Daiana Cristine Bündchen, Lourenço Sampaio de Mara, Véronique A. Cornelissen, Tales de Carvalho
      Purpose To compare the effect of high intensity interval training (HIIT) and moderate intensity continuous training (MICT) on physical fitness and quality of life (QoL) in patients with chronic heart failure (CHF). Methods Twenty-two male CHF patients (LVEF <45%, mean age 53.8±8yrs) were studied before and after 12weeks of supervised aerobic training for 60min, three times a week. Patients were randomly (1:1) to MICT (n=10) and HIIT (n=12). Both training programs involved treadmill exercise. The group MICT at 75% of peak heart rate (HR) and HIIT at ≈95% of peak HR. Outcome measurements included an assessment of QoL (Minnesota Living with Heart Failure Questionnaire (MLHFQ) and SF-36), measurements of 6-min walk test (6MWT) and peak oxygen consumption (VO 2 peak). Results Exercise was associated with a significant increased of 6MWT in 19.4% and 23.1% from MCIT and HIIT, respectively (p<0.001), but not between-group differences. It was observed an improvement in VO2peak by 11.2% in the HIIT group and 8.3% in the MCIT group, with between-group differences (p<0.01). Quality of life improved significantly and in all domains in both groups (p-value time-effect). All patients showed significant improvements in all domains from baseline, it was observed in both groups (p<0.05), with between-group differences for functional capacity (SF-36). No changes were observed in pain (SF-36) for both groups Conclusion Both training programs were equally effective in improving QoL and functional capacity in CHF patients. Trial Registration ( RBR-6hk9p6; registered on 15 May 2013.

      PubDate: 2015-11-24T22:59:17Z
  • Pharmacodynamic evaluation of clopidogrel reloading vs. switching to
           prasugrel or ticagrelor in clopidogrel resistant Indian patients

    • Authors: Sandeep Khasa; Roopali Khanna Fauzia Ashfaq Pravin Goel
      Abstract: Publication date: Available online 11 November 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Sandeep Khasa, Roopali Khanna, Fauzia Ashfaq, Pravin K. Goel
      Objectives To compare the pharmacodynamic effects of clopidogrel reloading vs.switching to prasugrel or ticagrelor in High on treatment platelet reactivity(HTPR) patients undergoing percutaneous coronary intervention(PCI). Methods Prospective,single-centre study wherein consecutive patients undergoing nonemergent PCI showing HTPR on 600mg clopidogrel loading were randomized to either clopidogrel reloading(300mg load,75mg OD)or prasugrel(60mg load,10mg OD-in patients>60kg) or ticagrelor(180mg load,90mg BD). HTPR defined as maximum platelet aggregation(MPA)>46% assessed by 5μmol/L adenosine diphosphate light transmission aggregometry(ADP-LTA) assay after more than 6h of clopidogrel loading. Platelet function were assessed at baseline,6h or more after clopidogrel loading,2h after reloading, day1 and day30 post PCI. Results 107 patients enrolled in study, 32(29.9%) were found to have HTPR.10(9.3%) patients were reloaded with clopidogrel,10(9.3%)with prasugrel and 12(11.2%)with ticagrelor. Mean MPA in clopidogrel, prasugrel and ticagrelor reloaded patients was 42.6±12.5%,15.8±8.6% and 14.6±7.2% respectively at 2h after reloading and was 43.7±13.5%,15.4±5.6% and 12.6±4.6% on day 1 post PCI. The MPA significantly reduced in prasugrel and ticagrelor cases and not in clopidogrel, also prasugrel and ticagrelor had almost similar MPA after the reload. There was no patient with continued HTPR with ticagrelor or prasugrel while 50% (5/10) of clopidogrel reloaded patients had HTPR. The pharmacodynamic efficacy of maintenance with prasugrel or ticagrelor was better than clopidogrel(MPA at day30 post PCI; 15±9.7%,13.9±5.1% and 50.4±13.1% respectively). Conclusion In patients undergoing PCI exhibiting HTPR after clopidogrel loading, ticagrelor or prasugrel reloading produced improved platelet inhibition which was better than clopidogrel reload and this effect was sustained during maintenance phase.

      PubDate: 2015-11-14T22:00:25Z
  • Pentraxin 3 genotyping in relation to serum levels of pentraxin 3 in
           patients with acute ST-segment elevation myocardial infarction

    • Authors: Ehab Melegy; Eman Badr Ahmed ElKersh Wassam Shafey Walaa Fareed
      Abstract: Publication date: Available online 11 November 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Ehab K. El Melegy, Eman A. Badr, Ahmed M. ElKersh, Wassam H. EL Shafey, Walaa A. Fareed
      Objective The aim of the study was to investigate the association of serum Pentraxin 3 and genotyping with the risk of developing AMI and its severity. Patients and methods Fifty patients admitted to the coronary care unit presented with STEMI (acute ST segment myocardial infarction) at the Cardiology Department, Menoufia University Hospital in the period from October 2014 to April 2015 and another 20 subjects age- and gender-matched were taken as the control group. All patients and controls were subjected to full history taking, clinical examination, ECG and echocardiography and measurement of lipid profile, cardiac biomarkers and serum pentraxin 3 concentration. The SNP rs2305619 pentraxin 3 genotyping by real time PCR. Results The patients with myocardial infarction had significantly higher levels of pentraxin 3 than the controls. The cut-off values for PTX3 and troponin I were 4.35ng/ml and 0.34μg/l respectively. Pentraxin 3 showed the highest diagnostic accuracy of coronary artery disease (96%), with sensitivity (96%) and specificity (95%). The highest serum pentraxin 3 levels were in the AA mutant homozygous type. Conclusion PTX3 is one of the earliest biomarkers for detecting acute coronary syndrome. rs2305619 AA genotyping of the pentraxin 3 gene might be a candidate risk factor for development of coronary artery disease, presumably by increased pentraxin 3 levels.

      PubDate: 2015-11-14T22:00:25Z
  • AMI in very young (aged ≤35years) Bangladeshi patients: Risk factors
           & coronary angiographic profile

    • Authors: Fazila-Tun-Nesa Malik; Md. Kalimuddin Nazir Ahmed Mohammad Badiuzzzaman Mir Nesaruddin
      Abstract: Publication date: Available online 11 November 2015
      Source:Clinical Trials and Regulatory Science in Cardiology
      Author(s): Fazila-Tun-Nesa Malik, Md. Kalimuddin, Nazir Ahmed, Mohammad Badiuzzzaman, Mir Nesaruddin Ahmed, Ashok Dutta, Dhiman Banik, Md. Kabiruzzaman, Habibur Rahman, Tawfiq Shahriar Huq, Md. Farhad Jamal
      Background Coronary artery disease is a devastating disease precisely because an otherwise healthy person in the prime of life may die or become disabled without warning. When the afflicted individual is under the age of 35, the tragic consequences for family, friends, and occupation are particularly catastrophic and unexpected. The purpose of the present study was to assess the risk factors, angiographic profile, and in-hospital outcome of very young patients (aged ≤35years) with first acute myocardial infarction (AMI). Methods A cross-sectional study was conducted involving 266 young (≤35years) patients with clinical diagnosis of AMI. They were studied for risk factors, clinical characteristics, and in-hospital outcome between February 2012 and October 2014 at the NHFH&RI, Dhaka, Bangladesh. Coronary angiography was done in 230 patients. Results The mean age of patients was 31.19±3.81years; 94.7% were male. The major risk factor was smoking, followed by dyslipidaemia, family history of ischemic heart disease. The most common anatomical location for the MI was the anterior wall. Significant coronary artery disease was found in 83.04% patients, 7.39% patients had normal coronaries. Most patients had single vessel disease followed by double-vessel disease. Left anterior descending was the commonest vessel involved followed by left circumflex artery. In-hospital mortality was 2.3%. Conclusion AMI in very young almost exclusively occurs in male and smoking was the most common risk factor. Acute anterior MI owing to occluded left anterior descending artery was more frequent. Very young patients with an AMI have a favorable in-hospital mortality.

      PubDate: 2015-11-14T22:00:25Z
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-